openPR Logo
Press release

Sarcoma Drugs Market – Qualitative Benefits 2028 | Novartis, Amgen, Eli Lilly

11-12-2018 11:21 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: TMR Research

/ PR Agency: TMR Research
Sarcoma Drugs Market – Qualitative Benefits 2028 | Novartis,

Global Sarcoma Drugs Market: Overview

A sarcoma, a rare form of cancer, differs from the more common carcinomas in one major way – they occur in a different type of tissue known as connective tissue. Those are essentially cells that support or connect other types of tissue in the human body. Sarcoma is highly common in muscles, bones, fats, nerves, cartilage, and blood vessels in one’s arms and legs. They can, however, also happen in other areas in the body.

Request Sample Copy of the Report @
https://www.tmrresearch.com/sample/sample?flag=B&rep_id=3825

The report on the global sarcoma drugs market finds that the market would rise at a healthy clip owing to emergence and acceptance of novel sarcoma drugs for treatment, a solid pipeline in the development phase, increasing allocation on research and development, and growing occurrence of soft tissue sarcomas.

Global Sarcoma Drugs Market: Drivers and Restraints

At present, chemotherapy regimens and targeted therapy are the two popular form of cure in the sarcoma drugs market. Between the two, the targeted therapy is predicted to see greater uptake in the near term because of its greater efficacy. Such treatments make use of drugs or antibodies formulated from the immune system to thwart proliferation of harmful cancer cells while leaving out the normal cells undamaged.

Other popular forms of cure in the sarcoma drugs market are surgeries in which the tumor is removed from the body or radiation in which the tumor cell is shrunk before surgery or the remaining cells killed post.

Request TOC of the Report @
https://www.tmrresearch.com/sample/sample?flag=T&rep_id=3825

A noticeable trend in the global sarcoma drugs market is money and efforts being expended for numerous immune-oncology agents. The sarcoma drugs has also received a major boost from the approval of new chemotherapy drugs, namely Johnson & Johnson’s Yondelis and Eisai’s Halaven. They have a far greater efficacy than the earlier anthracycline-based treatment regimens.

Global Sarcoma Drugs Market: Trends and Opportunities

There are 50 different types of sarcomas known today. Those can be broadly classified into bone sarcoma (osteosarcoma) and soft tissue sarcoma. The soft tissue sarcoma currently account for almost 87.0% of all sarcoma cases. Bone sarcomas, which are considered malignant, account for just 13.0% of all cases. Hence, the soft tissue sarcomas currently present maximum opportunity in the global sarcoma drugs market.

There are almost 45 drugs in the clinical pipeline in the global sarcoma drugs market. Besides, cancer vaccines and gene therapy are also emerging as potential treatments for soft tissue cancer. Numerous monoclonal antibodies and small molecules are in active development in Phase I and II trials as well.

Global Sarcoma Drugs Market: Regional Analysis

From a geographical standpoint, the U.S. at present forms the nerve center of the global sarcoma drugs market. Presence of a clutch of key players in the region, high government allocations towards research and development for sarcoma drugs, higher per capita medical spends of people, state-of-the-art research and healthcare facilities, and most importantly more number of sarcoma cases in the region have majorly fuelled its market.

The European Union region is also a crucial sarcoma drugs market because of the greater understanding of tumor microenvironment predicted to occur in the next couple of years thereby resulting in development of new patient-specific therapies.

Read Comprehensive Overview of Report @
https://www.tmrresearch.com/sarcoma-drugs-market

Global Sarcoma Drugs Market: Competitive Landscape

Some of the prominent participants in the global sarcoma drugs market that have been profiled in the report are Novartis, Amgen, Eli Lilly, Pfizer, Eisai, Johnson & Johnson, and Bayer. Besides throwing light on their products, the report also studies late-stage pipeline products of certain companies. The report observes savvy companies are embarking upon collaborations for conducting clinical trials, development, and broader product portfolios to bolster their positions in the global sarcoma drugs market.

About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends. Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sarcoma Drugs Market – Qualitative Benefits 2028 | Novartis, Amgen, Eli Lilly here

News-ID: 1361384 • Views: 183

More Releases from TMR Research

KEY OPINION LEADER MANAGEMENT MARKET SCOPE, SEGMENTATION, DEVELOPMENT AND OPPORT …
Global Key Opinion Leader Management Market: Snapshot Key opinion leaders (KOLs) are trustworthy, influential, and experts of a particular field in the healthcare industry. Relationships of a firm with these KOLs is of great importance to manage and build a strong healthcare profile. These key opinion leaders go a long way towards educating the scientific and medical communities as well as help in increasing awareness pertaining to the recent developments in
SMART WATER GRID MARKET NEWER SEGMENTS OF APPLICATION 2025
Global Smart Water Grid Market – Snapshot The global smart water grid market is foreseen to experience its development prodded on the back of the prerequisite of managing old infrastructure, rise in information and communication technology (ICT), gap between supply and demand, water shortage, and several other factors. So as to guarantee smooth supply of water and keep a tab on its equal supply, smart water grid technology is expected to
DIGITAL UTILITY MARKET EXPANSION PROJECTED TO GAIN AN UPTICK DURING 2025
Global Digital Utility Market: Snapshot In the midst of surging demand for quick digitalization and green energy in the energy segment, the interest for digital utility system is rising notably. Penetration of digital innovations in the vitality sector and programs in nations, for example, India and China expected to fulfil local needs are foreseen to feed the demand for digital utility solutions. Get Exclusive PDF Sample Copy Of This Report: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=3398 Rise in
WEB CONTENT MANAGEMENT MARKET VALUE PROJECTED TO EXPAND BY 2025
Global Web Content Management Market: Snapshot The global web content management market is anticipated to gain impetus due to the need for organizing and appropriately using content across various marketing channels such as social media and mobile, and not just the web. Web content management allows users to have a seamless web experience while helping organizations to digitally market their products and services. It helps both technical and non-technical users to

All 5 Releases


More Releases for Sarcoma

Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma
Kaposi Sarcoma Treatment Market Competitive Landscape
Kaposi sarcoma is a malignant tumor disease majorly associated with skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma causes lesions to grow in the skin, in the mucous membranes lining the mouth, nose, and throat, lymph nodes, and other organs. Human herpesvirus-8 (HHV-8) is majorly found in the lesion of all patients suffering from Kaposi sarcoma. However, patients with weakened immune systems by Acquired Immune Deficiency Syndrome (AIDS)
Kaposi Sarcoma Market Analysis & Trends 2024
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in
AIDS-related Kaposi’s Sarcoma Market Report 2017
AIDS-related Kaposi’s sarcoma is a type of cancer affecting the cells lining, the blood vessels, or lymph nodes. The cancer usually occurs as tumors on skin or mucosal surfaces. It is characterized by brown, red, or purple tumors on the affected area generally called as lesions. The major factors playing the role in the pathogenesis of the cancer are Kaposi’s sarcoma herpes virus/human herpes virus type 8 (KSHV/HHV-8), altered responses
AIDS- Related Kaposi's Sarcoma-Pipeline Insights, 2017
Orbis Research delivers key insights on the global AIDS- Related Kaposi’s Sarcoma market in a new report titled “AIDS- Related Kaposi’s Sarcoma-Pipeline Insights, 2017” In this report, Orbis Research sheds light on the various factors and trends impacting market growth over the forecast period (2017 – 2022). “AIDS - Related Kaposi's Sarcoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the AIDS
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of